Surface Oncology Inc

NASDAQ:SURF  
7.93
+0.42 (+5.59%)
Earnings Announcements

Surface Oncology Reports Q4 Earnings Per Share $1.56

Published: 03/09/2021 15:06 GMT
Surface Oncology Inc (SURF) - Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2020.
Q4 Earnings per Share $1.56.
Q4 Earnings per Share Estimate $-0.05 -- Refinitiv Ibes Data (analyst estimates).
Q4 Revenue $87.6 Million Versus $1.0 Million.
Q4 Revenue Estimate $17 Million -- Refinitiv Ibes Data (analyst estimates).
Continues to Project Cash Runway Sufficient Through 2023.
New Collaboration With Merck Will Evaluate Srf388, Targeting Il-27, in Combination With Keytruda in Patients With Solid Tumors.
Investigational New Drug (ind) Filing for Srf813 Anticipated in 2021.
Revenue is expected to be $7.5 Million
Adjusted EPS is expected to be -$0.28

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.43

More details on our Analysts Page.